Nxera wins $35m after Phase II schizophrenia trial success - Clinical Trials Arena
Nxera Pharma received $35m from Neurocrine Biosciences after positive Phase II trial data of NBI-568 in schizophrenia, potentially leading to $2.6bn total and $202m in sales by 2030. The trial met primary endpoint with a 20mg dose significantly reducing symptoms, advancing to Phase III in 2025. Current treatments have significant side effects, driving demand for new medications targeting both positive and negative schizophrenia symptoms.
Highlighted Terms
Related News
Nxera Pharma received $35m from Neurocrine Biosciences after positive Phase II trial data of NBI-568 in schizophrenia, potentially leading to $2.6bn total and $202m in sales by 2030. The trial met primary endpoint with a 20mg dose significantly reducing symptoms, advancing to Phase III in 2025. Current treatments have significant side effects, driving demand for new medications targeting both positive and negative schizophrenia symptoms.